Introduction {#s1}
============

One prominent feature of many antidepressant drugs (ADs) is their antagonistic action at 5-HT~2C~ receptors (5-HT~2C~R). Other ADs, including selective serotonin reuptake inhibitors, increase extracellular 5-HT concentration, and their chronic administration markedly decreases behavioral responses to 5-HT~2C~R agonists ([@CIT0080]; [@CIT0053]), suggesting 5-HT~2C~R desensitization. In this context, mutant rodents lacking the 5-HT reuptake carrier (5-HTT) are an interesting tool, which displays high extracellular 5-HT levels ([@CIT0019]; [@CIT0069]; [@CIT0033]) and decreased behavioral responses to the anxiogenic 5-HT~2C~R agonist m-chlorophenylpiperazine (mCPP; [@CIT0052]; [@CIT0055]). However, behavioral studies are insufficient to infer that authentic 5-HT~2C~R desensitization underlays the reduced 5-HT~2C~R--mediated responses, because causal alterations might occur at neurotransmitters and neuronal circuits downstream of 5-HT~2C~R.

5-HT~2C~R are positively coupled to phospholipase C, mobilizing intracellular Ca^2+^ and subsequently triggering cell signaling processes, such as the transcription of immediate early genes (IEGs). Many *in vitro* studies indicate rapid (minutes/hours) decrease/inactivation of this signaling function in response to elevated concentrations of 5-HT ([@CIT0001]; [@CIT0068]). In contrast, AD treatments require several days to weeks to induce tolerance of behavioral responses to 5-HT~2C~R agonists (for a review, see [@CIT0047]). Furthermore, whereas *in vitro* desensitization can reverse rapidly, *in vivo* tolerance remains for hours/days after AD treatment ([@CIT0053]). The extrapolation of *in vitro* desensitization data to *in vivo* regulatory tolerance processes is therefore not straightforward. Furthermore, differential desensitization might occur in various brain areas depending on 5-HT~2C~R density and other factors (pre-mRNA editing, constitutive activity, etc.). We thus used various approaches to assess mechanisms possibly contributing to the apparent 5-HT~2C~R desensitization inferred from behavioral investigations in 5-HTT^-/-^ mice. In particular, 5-HT~2C~R--mediated negative feedback on 5-HT release, a mechanism mainly occurring under high serotonergic tone conditions and stress ([@CIT0053]), allowed us to set up an *in vivo* biochemical assay to assess the functional state of 5-HT~2C~R in specific brain areas of 5-HTT^-/-^ mice.

Particular focus was put on the frontal cortex (FC), an area of interest regarding anxiety and depression ([@CIT0044]; [@CIT0062]). We investigated whether the decrease in 5-HT~2C~R responses could be explained by changes in expression of the 5-HT~2C~R protein and/or mRNA or pre-mRNA editing ([@CIT0077]). Interestingly, 5-HT~2A~ receptor desensitization had already been shown in the cortex of 5-HTT^-/-^ mice by measuring regional brain phospholipase A2 response to a preferential 5-HT~2A~R agonist (DOI; [@CIT0065]). Unfortunately, a similar assay to measure coupling with the Gα~q/11~ protein cannot be used in the case of 5-HT~2C~R because of relatively low receptor density in all brain regions, except the choroid plexus ([@CIT0045]). Therefore, we set up an *in vivo* 5-HT~2C~R signaling assay that consisted of quantifying 5-HT~2C~R--induced *c-fos* mRNA in 5-HT~2C~R--immune-positive cells. This assay was performed in stress-free handling conditions and was adapted for stereological quantification of *c-fos* mRNA at the cell level. Changes in anxiety-related behaviors were tentatively interpreted in view of alterations in 5-HT~2C~R function found at both the brain and cellular levels.

Materials and Methods {#s2}
=====================

Animals {#s3}
-------

Male mice, issued from the C57Bl/6J strain (F10), expressing or not expressing the 5-HT transporter (5-HTT^+/+^ and 5-HTT^-/-^ mice), were generated by the group of KP Lesch ([@CIT0007]) and were bred in our Paris laboratory.

Experiments performed in 8--16-week-old mice were carried out under standard laboratory conditions (12h light-dark cycle, lights on at 07:00h, temperature 21±1°C) with free access to food and water. For at least 30 minutes before each behavioral study, animals were left quiet in a room nearby the experimental room. All the procedures utilizing animals were conducted in full agreement with institutional guidelines (council directive no. 87--848, October 19, 1987, MAF, protocol agreement 0096.02 and authorization \# 75--977 to LL).

Pharmacological Treatments {#s4}
--------------------------

Although the preferential 5-HT~2C~R agonists used here--- (S)-6-Chloro-5-fluoro-1H-indole-2-propanamine (RO-60,0175) and mCPP---also have some agonist activity at other 5-HT receptor types (5-HT~2B~ and 5-HT~1B~ receptors, respectively), their effects in the various tests used in our studies were previously shown to be prevented by the selective 5-HT~2C~R antagonist, SB-242,084 ([@CIT0043]; [@CIT0037]; [@CIT0028]; [@CIT0053]), indicating their mediation essentially through 5-HT~2C~R activation. Even though mCPP is less selective than RO-60,0175, it was used in the social interaction test, because at the low systemic dose used in our studies (0.3mg/kg i.p.), mCPP triggers 5-HT~2C~R--mediated anxiety without causing hypolocomotion, which could possibly interfere with the anxiety-related response in this test ([@CIT0053]). Sigma-Aldrich and Tocris manufactured the mCPP and RO-60,0175 (as hydrochloride salts), respectively. Both drugs were dissolved in 0.9% NaCl with a brief sonication just prior to i.p. administration in mice.

Behavioral Studies {#s5}
------------------

### Novelty-Suppressed Feeding Test {#s6}

Mice were isolated and food-deprived for 30h before the experiment. They were then placed in a brightly lit (450 lux) open arena (40 x 40cm) without bedding. Food pellets were placed at the center and latency to feed (with a cut-off time of 300 s) was measured, using video recording, from the time the mouse was placed in the arena. Latency to feed was also measured in the home cage.

### Social Interaction Test {#s7}

Following two consecutive days of habituation to the social interaction arena (40 x 40cm; [@CIT0053]), mice of the same genotype and unfamiliar to each other were paired and injected with mCPP (0.3mg/kg i.p.), then kept in individual cages for 30 minutes before placing them in the dimly lit arena (5 lux). Fresh bedding was renewed after each test.

Animal behaviors were recorded with a camera, and analyzed by an observer unaware of the treatment groups. Active social interaction events (sniffing, fighting, chasing, grooming, etc.) were scored using ODlog (Macropod Software). In our test conditions, social interactions were rarely aggressive. Total social interactions scored reflected all types of active social interactions, but not passive contacts.

### Locomotor Activity Test {#s8}

Activity was measured using a computer-based photo-beam apparatus (Actisystem II, Panlab). Actimeter boxes (area: 30 x 15cm; height: 18cm; with grid floor) detected mouse movements by means of infrared light beams. Mice were placed in the boxes 30 minutes after i.p. administration of saline or the 5-HT~2C~R agonist RO-60,0175 (3mg/kg) and horizontal activity was monitored for 15 minutes ([@CIT0053]).

Measurement of 5-HT Turnover {#s9}
----------------------------

Tissue levels of 5-HT and its metabolite 5-hydoxyindoleacetic acid (5-HIAA) were determined in the amygdala, FC, hippocampus, nucleus accumbens (Acb), and ventral tegmental/substantia nigra (VTA/SN) using HPLC-ED detection, as previously described ([@CIT0053]; see [Supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu056/-/DC1)).

For some animals, saline or RO-60,0175 (3mg/kg) was administered i.p. 30 minutes before restraint stress, performed by placing mice inside a 50mL syringe, perforated at the tip to allow them access to air. Mice were sacrificed immediately after restraint stress (45min), and HPLC-ED determinations of 5-HT and 5-HIAA proceeded as described ([@CIT0053]).

Histological Assays {#s10}
-------------------

### Characterization of the 5-HT~~2C~~R Antibody {#s11}

The polyclonal 5-HT~2C~R antibody Ab32172 (Abcam) was characterized using Chinese hamster ovary (CHO-K1) cells, which do not natively express 5-HT~2A~R or 5-HT~2C~R mRNA ([@CIT0008]; [@CIT0002]). CHO-K1 cells were transiently transfected with the rat 5-HT~2C~R encoding sequence, which shares 96% homology with the mouse 5-HT~2C~R at the level of the domain (amino acids 400--460) recognized by the antibody (Abcam). Plasmids encoding the rat 5-HT~2C~R (RR207006, OriGene), 5-HT~2A~R (generously provided by Dr Bryan L. Roth; [@CIT0009]), or empty vector were transfected overnight into CHO-K1 cells using lipofectamine 2000 (Invitrogen), following the manufacturer's protocol. The following day, transfected cells were seeded on coverslips and grown overnight (37°C, 5% CO~2~). They were then fixed in 3% paraformaldehyde for 30min and washed in Tris buffer (50mM Tris-HCl, 500mM NaCl, 0.6% Tween-20, pH 7.5) before blockade with 3% normal donkey serum in Tris buffer for 1h at room temperature. Incubation with 5-HT~2C~R antibody Ab32172 (1:400) or 5-HT~2A~R antibody Ab16028 (1:400; Abcam) was then performed overnight at 4°C, prior to exposure to Alexa Fluor 555 donkey anti-rabbit IgG (1 hour at room temperature; 1:1000; Life Technologies). Then, coverslips were mounted with Vectashield fluorescent medium containing DAPI (Vector Laboratories). All images of CHO-K1 cells were taken with an Olympus BX51 fluorescent microscope (objective 40x) and Hamamatsu digital camera without additional zoom, using identical exposure settings across all slides.

### Intravenous Injections and Tissue Preparation {#s12}

Intravenous catheter surgery was carried out as previously described ([@CIT0073]). Mice were anesthetized with a ketamine⁄xylazine mixture (5:1; 1 mL⁄100g body weight, i.p.) and then implanted with an indwelling i.v. silastic catheter. A 5cm length of silastic tubing (0.3mm inner diameter, 0.6mm outer diameter; Silastic®, Dow Corning) was fitted to a 22-gauge steel cannula (Semat) that was bent at a right angle and then embedded in a cement disk (Dentalon Plus) with an underlying nylon mesh. The catheter tubing was inserted 1.3cm into the right jugular vein and anchored with suture. The remaining tubing ran subcutaneously to the cannula, which exited at the midscapular region. All incisions were sutured and coated with an antibiotic ointment. Following surgery, mice were individually housed and allowed to recover for 4 days prior to drug administration. The day of the experiment, mice were connected to the injection apparatus and left quiet and alone for at least 3 hours. Mice were then remotely injected i.v. with either the vehicle (sterile 0.9% NaCl) or RO-60,0175 (0.3mg/kg; 12.5 µl; [@CIT0017]). The catheter was flushed with sterile saline 1 minute before drug administration to prevent clogging.

Thirty minutes later, the animals were decapitated and their brains were dissected on ice, cut in 3mm coronal slabs containing the FC, and fixed in a 4% paraformaldehyde solution (Sigma-Aldrich). After this fixation step, the brain slabs were put in a solution of sucrose (30%) overnight at 4°C before being stored at -20°C in a cryoprotectant solution (adapted from [@CIT0074]; sucrose 30% w/v, polyvinylpyrrolidone 1% w/v, ethylene glycol 30% v/v, 0.2% ProtectRNA™ \[Sigma-Aldrich\] in phosphate buffered saline \[PBS\] treated with 0.05% v/v of diethyl-pyrocarbonate \[DEPC-PBS; Sigma-Aldrich\] before autoclaving). On the experiment day, the slabs were washed in cold-DEPC-PBS, cut at 40 µm using a vibratome, and kept in well-meshes (Costar).

### 5-HT~~2C~~R Immunohistochemistry Coupled to c-fos mRNA *In Situ* Hybridization {#s13}

ProtectRNA™ 0.2% and DEPC-treated components were used throughout the immunohistochemistry procedure to prevent mRNA degradation before the *in situ* hybridization assay, performed 3 days later.

The 5-HT~2C~R immunohistochemistry assay (with the Ab32172^®^) followed by the *c-fos* mRNA *in situ* hybridization assay, were performed as previously described ([@CIT0051]; [@CIT0046]; see [Supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu056/-/DC1)).

### Stereological Analysis {#s14}

Preliminary tests confirmed that all antibodies adequately penetrated inside the 40 µm--thick sections. Stereology analysis was performed using a semiautomatic stereology computer-based system (Mercator; ExploraNova). Counting outlines of the FC (including infralimbic and prelimbic cortices) were defined at low magnification (4x) according to the mouse brain atlas ([@CIT0060]). Doubled, stained *c-fos* mRNA and 5-HT~2C~R--like immunoreactive (IR) cells were counted at high magnification (63x) using the Optical Fractionator (50 x 50 x 20 µm^3^ counting bricks, randomly sampled) operated by the Mercator software using an automated stage. We defined a counting exclusion zone of 5 µm at the top and bottom of the sections to avoid biases.

The sampling error, which takes into account the variability both within sections and between sections, was always ≤5% (Schaeffer test). Volumes (in mm^3^) and density estimation (number of cells/mm^3^) were measured.

5-HT~2C~R mRNA Quantification by RT-qPCR {#s15}
----------------------------------------

Mice were decapitated and their brains were immediately dissected on ice. The FC was isolated and kept in liquid nitrogen, then stored at -80°C. RNA extraction and quantification were done as described in the [Supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu056/-/DC1).

Measurements of Pre-mRNA Editing {#s16}
--------------------------------

The FC was isolated and stored as for RT-qPCR determinations. Purified mRNA samples were extracted and treated with DNAse (DNAse kit, Invitrogen). Total RNA was linearized before reverse transcription using a reverse transcriptase kit (Thermoscript Real-Time Polymerase Chain Reaction system, Invitrogen). Nested-polymerase chain reaction (PCR) single-strand conformational polymorphism analyses, capillary electrophoresis, and the identification/relative quantification of each isoform were then performed as previously described ([@CIT0061]; see [Supplementary Material](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu056/-/DC1)).

Statistics {#s17}
----------

Data for most behavioral tests, the quantitative RT-PCR, and the 5-HT~2C~R--like IR-cells density were all analyzed by the student's *t*-test, comparing 5-HTT^-/-^ mutants and 5-HTT^+/+^ mice. The effect of *meta*-chlorophenylpiperazine (mCPP) in the social interaction test was analyzed using a two-way analysis of variance (ANOVA) followed by the Bonferroni's post hoc test.

The effect of RO-60,0175 on the stress-induced increase of 5-HT turnover was analyzed with a three-way ANOVA using the brain area, drug treatment, and genotype as factors, and then two-way ANOVAs to assess the effect of the drug treatment in each brain area independently, and the genotype effects as a function of brain areas in either the RO-60,0175 or saline conditions. Pairwise comparisons were done using the Bonferroni's post hoc test. Stereological histological data was analyzed by two-way ANOVA to assess the respective effects of treatment and genotype.

Results {#s18}
=======

Behavioral Features in 5-HTT^-/-^ Versus 5-HTT^+/+^ Mice {#s19}
--------------------------------------------------------

No differences were observed between 5-HTT^-/-^ and 5-HTT^+/+^ mice in latency to feed in their home cage ([Figure 1](#F1){ref-type="fig"}) or in spontaneous locomotor activity assessed in an actimeter (in counts per 15 minutes; 5-HTT^+/+^: 266±23; 5-HTT^-/-^: 238±53; means ± standard error of the mean \[SEM\]; n = 6; *p* \> 0.05 student's *t*-test). Mice were then tested in the novelty-suppressed feeding test (a standard model of anxiety commonly used to assess the anxiolytic effect of ADs; [@CIT0011]). The weight loss during the food-deprivation period that preceded the novelty-suppressed feeding test was not significantly different between the two genotypes (5-HTT^+/+^ = -20±1.6 %; 5-HTT^-/-^ = -17.3±1.7 %; n = 4; *p* \> 0.05, student's *t*-test). However, a longer latency to initiate feeding was noted for 5-HTT^-/-^ mice in the unfamiliar environment ([Figure 1](#F1){ref-type="fig"}), indicating an anxiety-like profile compared to 5-HTT^+/+^ mice, as previously observed ([@CIT0041]; [@CIT0003]). However, in the social interaction test, 5-HTT^-/-^ mice did not appear more anxious ([Figure 1B](#F1){ref-type="fig"}), instead displaying a trend for more social interactions. Using the same test, we confirmed that a low dose of mCPP (0.3mg/kg, i.p) markedly reduced the time spent by 5-HTT^+/+^ mice in active social interactions (-68±8%), an effect previously shown to be mediated by 5-HT~2C~R activation ([@CIT0049]; [@CIT0053]). In contrast, mCPP was ineffective in 5-HTT^-/-^ mice ([Figure 1B](#F1){ref-type="fig"}).

![Anxiety-like profile and 5-HT~2C~ receptor-mediated hypolocomotion in mice lacking the 5-HT reuptake carrier (5-HTT^-/-^).\
(A) The latencies to feed were compared in food-deprived 5-HTT^-/-^ versus 5-HT reuptake carrying (5-HTT^+/+^) mice, placed in the novelty-suppressed feeding test (NSFT) arena or left in their home cage. Values are mean ± standard error of the mean (SEM; n = 7--8). Two-way ANOVA indicated a significant effect of environment \[F(1,27) = 27, *p* \< 0.0001\] and of genotype \[F(1,27) = 12.6, *p* = 0.001\], and a significant environment x genotype interaction \[F(1,27) = 7.4, *p* = 0.01\]. \**p* \< 0.001. Bonferroni's post hoc test indicated a significant effect of genotype in the NSFT arena. (B) Time spent in active social interaction in saline- or m-chlorophenylpiperazine (mCPP)-treated mice. Values are mean ± SEM (n = 6--7). Two-way ANOVA indicated a significant effect of genotype \[F(1,26) = 13.6, *p* = 0.001\] and no overall effect of mCPP \[F(1,26)= 2.4\], but a significant genotype x mCPP interaction \[F(1,26) = 8.3, *p* \< 0.01\]. Bonferroni's post hoc test indicated a significant effect of genotype in the mCPP groups (\**p* \< 0.001) and a significant effect of mCPP vs. saline-only treatment in the 5-HTT^+/+^ group (\#*p* \< 0.05). (C) The hypolocomotion induced by RO-60,0175 in 5-HTT^+/+^ mice (in counts/15min; saline: 266±23; RO: 159±15; means ± SEM, - 40.2±6 %, n = 6, *p* \< 0.01) was not observed in 5-HTT^-/-^ mice (saline: 238±53; RO: 277±17; +16±7 %; n = 6, n.s.). \**p* ≤ 0.001; student's *t*-test comparing the percentage inhibition of locomotion produced by RO-60,0175.](ijnppy_pyu056_f0001){#F1}

Although mCPP is the drug of choice to induce anxiety via 5-HT~2C~R, with minimal locomotor effects when used at low doses (\<1mg/kg i.p.; [@CIT0053]), the more selective agonist, RO-60,0175, was previously demonstrated to be more appropriate for assessment of 5-HT~2C~R--mediated hypolocomotion ([@CIT0048]). Accordingly, we noted that RO-60,0175 (3mg/kg i.p.) induced a 40±6 % (n = 6) reduction in locomotor activity in 5-HTT^+/+^ mice. In contrast, no hypolocomotor effect of RO-60,0175 (3mg/kg i.p.) was observed in 5-HTT^-/-^ mice ([Figure 1C](#F1){ref-type="fig"}).

Brain 5-HT Turnover in 5-HTT^-/-^ Versus 5-HTT^+/+^ Mice {#s20}
--------------------------------------------------------

Significant differences in basal 5-HT turnover in 5-HTT^-/-^ versus 5-HTT^+/+^ mice were observed in three out of the five brain areas examined ([Table 1](#T1){ref-type="table"}). Indeed, 5-HIAA/5-HT ratios in the Acb (+35±3%), hippocampus (+78±7%), and particularly the VTA/SN (+112±6%) were significantly higher in mutants than in wild-type mice, and marginally increased in the FC. In contrast, this ratio did not differ between strains in the amygdala ([Table 1](#T1){ref-type="table"}), although both 5-HIAA and 5-HT tissue levels were similarly decreased in the latter area, as in all brain areas examined in mutants (see [Supplementary Table 1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyu056/-/DC1)), in line with previous reports ([@CIT0019]; [@CIT0038]).

###### 

The effect of genetic invalidation of 5-HTT on basal 5-HT turnover in various brain areas.

                   5-HTT^+/+^   5-HTT^-/-^   *p*-value
  ---------------- ------------ ------------ --------------
  Accumbens        0.46±0.02    0.62±0.01    *p* \< 0.001
  Amygdala         0.50±0.04    0.56±0.02    n.s.
  Frontal cortex   0.52±0.03    0.63±0.04    *p* = 0.08
  Hippocampus      0.60±0.04    1.07±0.04    *p* \< 0.001
  VTA/SN           0.76±0.04    1.61±0.05    *p* \< 0.001

Values are mean 5-HIAA/5-HT ratio ± standard error of the mean (n = 6--8). *p*-values were determined with the student's *t*-test, comparing mice lacking (5-HTT^-/-^) and posessing (5-HTT^+/+^) the 5-HT reuptake carrier in each area. VTA/SN: ventral tegmental/substantia nigra.

Determination of the RO-60,0175 inhibitory effect on the stress-induced increase of 5-HT turnover also indicated differences between 5-HTT^-/-^ and 5-HTT^+/+^ mice ([Figure 2](#F2){ref-type="fig"}). Stress produced a similar increase in the 5-HIAA/5-HT ratio in most brain areas of both genotypes, except the amygdala, where the stress-induced increase in 5-HT turnover appeared twice as high in mutants as in wild-type mice ([Figure 2E](#F2){ref-type="fig"}). Furthermore, in contrast to what was observed in WT mice ([@CIT0053]), RO-60,0175 did not induce major inhibitory effects on the stress-induced increase of 5-HIAA/5-HT ratio in most brain areas of 5-HTT^-/-^ mice, except in the amygdala of 5-HTT^-/-^ mice, where the effect was nevertheless smaller than that observed in 5-HTT^+/+^ mice (5-HTT^-/-^ = -41±16%; 5-HTT^+/+^ = -88±16%; n = 10; mean ± SEM, *p* = 0.05 in student's *t*-test; [Figure 2E](#F2){ref-type="fig"}). Three-way ANOVA with repeated measures indicated a significant effect of the drug RO-60,0175 \[F(1,122) = 37, *p* \< 0.0001\], of genotype \[F(1,122) = 21, *p* \< 0.0001\], and a significant drug x genotype interaction \[F(1,122) = 7, *p* \< 0.01\]. There were also significant differences in the stress-induced increase of 5-HT turnover between brain areas \[F(4,122) = 10, *p* \< 0.001\] and an interaction between brain areas and genotype \[F(4,122) = 5, *p* \< 0.01\]. A two-way ANOVA using drug and genotype as factors indicated a significant effect of RO-60,0175 in all the brain areas tested (*p* \< 0.05-- 0.01): the Acb \[F(1,24) = 8.3\], amygdala \[F(1,31)= 9.4\], FC \[F(1,22)= 7.6\], hippocampus \[F(1,23)=8.8\], and VTA/SN \[F(1,21) = 10.5\]. There was also a significant effect of genotype in the amygdala \[F(1,31) = 16.2, *p* \< 0.001\] and in the hippocampus \[F(1,23) = 11.6, *p* \< 0.01\]. The drug x genotype interaction reached significance only in the FC \[F(1,22) = 5.7; *p* \< 0.05\] and the Bonferroni's post hoc analysis revealed a significant effect of RO-60,0175 compared to saline treatment in 5-HTT^+/+^ mice (*p* \< 0.001), but not in 5-HTT^-/-^ mice ([Figure 2B](#F2){ref-type="fig"}).

![Effects of acute administration of RO-60,0175 (RO) on the stress-induced increase of 5-HT turnover in various brain areas of mice lacking (5-HTT^-/-^) and possessing (5-HTT^^+/+^^) the 5-HT reuptake carrier. ∆ 5-HIAA/5-HT values (5-HIAA/5-HT ratios in stressed mice minus the mean 5-HIAA/5-HT ratios found in naive mice) are mean ± standard error of the mean of n = 6--10 mice. In mutant mice, RO-60,0175 did not induce major inhibitory effects on the stress-induced increase of 5-HIAA/5-HT ratio in (a) the nucleus accumbens, (b) the frontal cortex, (c) the hippocampus, (d) the ventral tegmental/substantia nigra (VTA/SN), except in (e) the amygdala. Data were analyzed using the three-way analysis of variance (ANOVA) following by two-way ANOVAs (see text for details). \**p* \< 0.001 compared to saline-treated 5-HTT^+/+^ mice using Bonferroni's post hoc test after a two-way ANOVA (using drug and genotype as factors). \$*p* \< 0.05 compared to saline-treated 5-HTT^+/+^ mice and \#*p* \< 0.01 compared to RO-60,0175--treated 5-HTT^+/+^ mice using Bonferroni's post hoc test after two-way ANOVA (using brain areas and genotype as factors).](ijnppy_pyu056_f0002){#F2}

Two-way ANOVAs were also performed using brain areas and genotype as factors in each treatment condition. In the saline condition, there was a significant difference in the stress-induced increase in 5-HT turnover between areas \[F(4,55) = 7.43; *p* \< 0.0001\] and a significant area x genotype interaction \[F(4,55) = 2.78; *p* \< 0.05\], and the Bonferroni's post hoc test indicated that wild-type and mutant mice differed only in the amygdala (*p* \< 0.05). In the RO-60,0175 condition, there was also a significant difference in the stress-induced increase in 5-HT turnover between areas \[F(4,66) = 3.1; *p* \< 0.05\] and an effect of genotype \[F(1,66) = 29.6; *p* \< 0.001\], and the Bonferroni's post hoc test indicated that mice differed in the hippocampus (*p* \< 0.001) and in the amygdala (*p* \< 0.01).

Molecular and Cellular Investigations of 5-HT~2C~R Sensitivity in the Frontal Cortex of 5-HTT^-/-^ Versus 5-HTT^+/+^ Mice {#s21}
-------------------------------------------------------------------------------------------------------------------------

To unveil the molecular/cellular processes underlying the 5-HTT^-/-^-associated decrease in the 5-HT~2C~R function, as evidenced in the assays reported above, investigations were carried out at the mRNA and protein levels. RT-qPCR determinations first showed unaltered tissue levels of total 5-HT~2C~R encoding mRNA in the 5-HTT^-/-^ mutants, compared to the 5-HTT^+/+^ mice ([Figure 3A](#F3){ref-type="fig"}). Measurements of each editing isoform of 5-HT~2C~R pre-mRNA using nested-PCR followed by capillary electrophoresis ([@CIT0061]) showed that the predominant isoforms were those encoding the VNV, VSV, and VNI variants in both genotypes ([Figure 3B](#F3){ref-type="fig"}). However, no differences in the respective percentages of these or other variants were found in the FC of 5-HTT^-/-^ compared to 5-HTT^+/+^ mice ([Figure 3B](#F3){ref-type="fig"}).

![Cellular investigations of the apparent 5-HT~2C~R desensitization in the frontal cortex of mice lacking the 5-HT reuptake carrier (5-HTT^-/-^). The 5-HT~2C~R mRNA expression (A) and the quantitative distribution of 5-HT~2C~R mRNA isoforms expressed at more than 1% of total mRNA (B) are compared between 5-HTT^-/-^ and 5-HTT^+/+^ (posessing the 5-HT reuptake carrier) mice. Values are mean ± standard error of the mean (SEM) of (A) total 5-HT~2C~R mRNA normalized to GaPDH mRNA (*p* \> 0.05, student's *t*-test, n = 9--10) and (B) respective percentages of various 5-HT~2C~R mRNA isoforms over total 5-HT~2C~R mRNA (n = 5--6; only values above 1% are represented). The two-way analysis of variance (ANOVA) indicated a difference between isoforms \[F(9,90) = 1156, *p* \< 0.0001\], but no effect of genotype \[F(1,90) = 0.1\] and no interaction \[F(9,90) = 1\]. (C) To validate the Ab32172 antibody before its use in mouse cortical tissue, Chinese hamster ovary (CHO-K1) cells, which do not express 5-HT~2A~R or 5-HT~2C~R mRNA, were transiently transfected with either the 5-HT~2C~R (CHO-5-HT~2C~R) or 5-HT~2A~R (CHO-5-HT~2A~R) encoding vector or the empty vector (CHO-Empty Vector) and stained with Ab32172, followed by Alexa Fluor 555 secondary antibody (red) and counterstained with DAPI (blue). Significant immunofluorescence was observed in cells transfected with the 5-HT~2C~R, but not the 5-HT~2A~R or the empty vector. 5-HT~2A~R expression in 5-HT~2A~R-transfected CHO cells was confirmed by immunofluorescence using the 5-HT~2A~R antibody Ab16028 (data not shown). (D) The overall density of 5-HT2CR--like immunoreactive cells was determined in 5-HTT^-/-^ mutants compared to 5-HTT^+/+^ mice. Values are mean ± SEM of the total number of 5-HT2CR--like immunoreactive cells/mm^3^. There was no difference in the volume of the region investigated between mutants and wild-type mice (5-HTT^+/+^ = 0.97±0.03mm^3^; 5-HTT^-/-^ = 0.87±0.09mm^3^; means ± SEM, n = 6,). (E) Analysis of RO-60,0175--induced *c-fos* mRNA expression in 5-HT2CR--like immunoreactive cells, in 5-HTT^+/+^ and 5-HTT^-/-^ mice. Two-way ANOVA indicated a significant effect of RO-60,0175 \[F(1,8) = 13, *p* \< 0.01\] and no effect of genotype \[F(1,8) = 3\], but a significant RO-60,0175 x genotype interaction \[F(1,8) = 11, *p* = 0.01\]. The one-way ANOVA, followed by the Newman Keuls' test, indicated further differences \[F(3,8) = 9; *p* \< 0.01\]; \**p* \< 0.05 and \*\**p* \< 0.01 compared to saline-treated 5-HTT^+/+^ mice (n = 3). (F) Representative micrographs of double-stained cells (red arrows). 5-HT~2C~R--like immunopositive cells have brown deposits while digoxigenin-immunopositive cells have dark dots indicating the presence of *c-fos* mRNA (scale bar = 10 µm).](ijnppy_pyu056_f0003){#F3}

We then performed immunofluorescence labeling with a specific 5-HT~2C~R antibody. Prior experiments using CHO cells showed that this antibody (Ab32172) labeled cells transfected with the 5-HT~2C~R--encoding plasmid but not those transfected with the 5-HT~2A~R--encoding plasmid or the empty vector ([Figure 3C](#F3){ref-type="fig"}). As shown in [Figure 3D](#F3){ref-type="fig"}, quantitative estimates of immunohistochemical labeling by this anti-5-HT~2C~R antibody did not reveal differences in the density of 5-HT~2C~R--like positive cells in the FC between genotypes.

In contrast, combined 5-HT~2C~R and *c-fos* mRNA labeling ([Figure 3E](#F3){ref-type="fig"}) showed that, in saline-treated mice, the density of double IR cells in the FC was significantly higher in 5-HTT^-/-^ mutants than in 5-HTT^+/+^ mice ([Figure 3E](#F3){ref-type="fig"}). Furthermore, acute treatment with RO-60,0175 (0.3mg/kg i.v.) markedly increased the density of 5-HT~2C~R--positive *c-fos* mRNA-double IR cells in 5-HTT^+/+^ mice (+224±55%, *p* \< 0.01), but had no effect on these cells in 5-HTT^-/-^ mice ([Figure 3E](#F3){ref-type="fig"} and [F](#F3){ref-type="fig"}). However, in RO-60,0175-treated mice, the percentage of 5-HT~2C~R--like IR cells not expressing *c-fos* mRNA did not significantly differ between genotypes (5-HTT^+/+^: 44±9%; 5-HTT^-/-^: 56±4%) suggesting that the differential effect of the 5-HT~2C~R agonist in mutants versus wild-type mice could not be accounted for by a saturating capacity of 5-HT~2C~R--like IR cells, to be activated by RO-60,0175 in the mutants.

Discussion {#s22}
==========

5-HTT^-/-^ mice are a useful tool to model chronic 5-HT reuptake inhibition with ADs ([@CIT0031]). Nevertheless, the mutation is obviously not identical to an AD treatment, as many events taking place during development in 5-HTT^-/-^ mice do not occur during adulthood AD treatments. In fact, the developmental loss of 5-HTT was argued to alter mouse behaviors in models of depression and anxiety, but in opposite ways to those expected from AD treatments ([@CIT0003]). In humans, the 5-HTT polymorphism, generating a short variant allele of the 5-HTT promoter, reduces 5-HT reuptake capacity in homozygote individuals and predisposes them to affective disorders ([@CIT0039]; [@CIT0024]). In mice, an early deficit of 5-HT reuptake during development triggers an anxious phenotype in adulthood ([@CIT0003]; [@CIT0059]).

Most authors point to the anxiety phenotype of 5-HTT^-/-^ mice in standard tests ([@CIT0032]; [@CIT0013]), but these mice can be less---or at least not more---anxious than 5-HTT^+/+^ mice in other validated behavioral tests ([@CIT0041]; [@CIT0081]; [@CIT0058]). We clearly showed here ([Figure 1](#F1){ref-type="fig"}), that 5-HTT^-/-^ mutants had a longer latency to feed in the novelty-suppressed feeding assay, as previously reported ([@CIT0041]; [@CIT0003]; [@CIT0058]). Anxiety-related changes most likely explain this behavior, because latency to feed was unaffected under usual, non-anxiogenic, environmental conditions. Furthermore, previous studies showed that changes in 5-HTT expression do not, on their own, influence feeding behavior ([@CIT0063]). However, 5-HTT^-/-^ mutants were less responsive than 5-HTT^+/+^ mice to the anxiogenic compound mCPP in the social interaction test, another test shown to detect the effects of serotonergic agents on anxiety ([@CIT0012]; [@CIT0006]; [@CIT0020]). These results suggest that genetic 5-HTT invalidation alters circuits regulating conflict (inhibition of feeding in an anxiogenic context) but not those regulating social fear, in line with the well-established mediation of distinct aspects of fear and anxiety by different brain areas ([@CIT0026]). Interestingly, our results are also in accordance with those of [@CIT0055] who used a variant of the social interaction test that is often used to model the reduced social interaction in autism ([@CIT0056]). Finally, our behavioral investigations confirmed that the hypocolomotion normally induced by RO-60,0175 in wild-type mice was not observed in 5-HTT^-/-^ mice ([@CIT0052]; [@CIT0055]), further arguing for tolerance to 5-HT~2C~R agonists' effects.

In view of the neurodevelopmental changes caused by early 5-HT reuptake deficits, which lead to amygdala hyperactivity and fear ([@CIT0076]), it is retrospectively surprising that anxiety in 5-HTT^-/-^ mice is not unequivocal, as one might expect. Their behavioral phenotype may be moderated by an apparent desensitization of 5-HT~2C~R, notably in the cerebral cortex, as convergent data clearly demonstrated that a decrease in 5-HT~2~R function mediates anxiolysis ([@CIT0075]; [@CIT0029]; [@CIT0053]). The tolerance to 5-HT~2C~R agonist stimulation might not only be at the core of ADs' anxiolytic effect, but could also be a physiological compensatory phenomenon limiting anxiety symptoms in predisposed individuals. It was thus of utmost interest to determine how this putative desensitization occurs.

We previously showed that 5-HT~2C~R activation prevents the enhancement of brain 5-HT turnover and extracellular concentration triggered by restraint stress ([@CIT0053]). This indirect 5-HT~2C~R--mediated effect, which involves gamma-aminobutyric acid (GABA) ergic interneurons exerting a negative feedback on 5-HT release, probably plays a pivotal role in moderating the high serotonergic tone occurring during stress. However, an excessively low 5-HT tone at other receptors can limit stress-coping ability and ultimately lead to anxiety ([@CIT0035]). We used this GABA-mediated, 5-HT~2C~R, negative-feedback control of 5-HT turnover as an *in vivo* functional assay to assess the sensitivity of 5-HT~2C~R. A major decrement in the inhibitory effect of RO-60,0175 was observed in the FC of 5-HTT^-/-^ compared to 5-HTT^+/+^ mice. This change was very similar to that reported after chronic 5-HT reuptake inhibition with paroxetine in wild-type mice and may account for the behavioral phenotype observed here in the mutants ([@CIT0078]; [@CIT0053]). Deletion or chronic blockade of the 5-HTT very likely caused this tolerance via the sustained increase in extracellular 5-HT concentration reached in the vicinity of 5-HT~2C~R. Previous microdialysis studies have shown that extracellular 5-HT is increased in the hippocampus, striatum, and VTA/SN of 5-HTT^-/-^ versus 5-HTT^+/+^ mice ([@CIT0019]; [@CIT0069]; [@CIT0033]), which translated here into an increased 5-HT turnover ([Table 1](#T1){ref-type="table"}).

In the amygdala, acute administration of RO-60,0175 still produced a decrease in stress-enhanced 5-HT turnover in 5-HTT^-/-^ mutants ([Figure 2](#F2){ref-type="fig"}), probably because there were no genotype differences in basal 5-HT turnover in that area ([Table 1](#T1){ref-type="table"}). Interestingly, however, an increased 5-HT turnover did become apparent in the amygdala of stressed 5-HTT^-/-^ mutants ([Figure 2E](#F2){ref-type="fig"}). A possible explanation of these peculiar responses in the amygdala might be related to the higher expression of the organic cation transporter (OCT) 3 in this area compared to other brain areas ([@CIT0023]). Indeed, the non-specific monoamine OCTs are overexpressed in several brain areas of 5-HTT^-/-^ mice ([@CIT0014]; [@CIT0067]; [@CIT0005]), and this might compensate for the 5-HTT invalidation, as previously suggested by [@CIT0015]. In addition, OCT reuptake blockade by corticosterone released during stress ([@CIT0079]; [@CIT0004]; [@CIT0022]) might account, at least in part, for the enhanced, stress-induced increase of 5-HT turnover in the amygdala of 5-HTT^-/-^ mice.

Such specific alterations in the amygdala might be related to the increased anxiety-like phenotype of 5-HTT^-/-^ mice in some models, especially because an increased 5-HT~2C~R binding was observed in this area of the mutants ([@CIT0040]). But if more amygdala 5-HT~2C~R stimulation means more anxiety, this could not account for the reduced anxiogenic effect of mCPP in the social interaction test. However, because 5-HT~2C~R mRNA editing would lead to reduced 5-HT~2C~R functions *in vivo*, as inferred from clear-cut *in vitro* data on downstream 5-HT~2C~R--signaling pathways ([@CIT0050]), an increased 5-HT~2C~R mRNA editing in the amygdala of 5-HTT^-/-^ mice might contribute to the reduced anxiogenic effect of mCPP ([@CIT0055]). In fact, in contrast to the expectations created from *in vitro* data, mutant mice expressing only the fully-edited isoform of 5-HT~2C~R show an increase rather than a decrease in their responses to 5-HT~2C~R agonists ([@CIT0046]). Accordingly, the reduced anxiogenic effect of 5-HT~2C~R stimulation in 5-HTT^-/-^ mice is most likely accounted for by reduced sensitivity of 5-HT~2C~R in areas outside the amygdala, where there is no compensatory increase in 5-HT~2C~R density.

Among these brain areas, the FC appeared to us of special interest because it is interconnected with the amygdala; it is also involved in social anxiety regulation ([@CIT0062]), and a local decrease in 5-HTT binding has been found to correlate with depression ([@CIT0044]). In contrast to the amygdala, the FC in 5-HTT^-/-^ mutants displays increases in extracellular 5-HT ([@CIT0069]; [@CIT0033]) and a clear-cut reduction in 5-HT~2C~R--mediated inhibition of stress-induced 5-HT turnover ([Figure 2](#F2){ref-type="fig"}). In many brain areas, in particular the FC, the resulting increased tone at other 5-HT receptors probably has important consequences relevant to the anxiolytic/antidepressant effects, as well as some of the negative psychotropic side effects of sustained 5-HTT inhibition. Chronic 5-HTT blockage with ADs was previously shown to enhance 5-HT~1A~R--mediated inhibition of neural circuitry in the FC, in conjunction with attenuated effects related to 5-HT~2~R activation ([@CIT0010]). An optimized balance between the excitatory and inhibitory effects of 5-HT through various receptors (including 5-HT~2C~R and 5-HT~1A~R) is central to behavioral inhibition, impulsivity, and other controls over emotions operated by the FC ([@CIT0064]). It was thus crucial to determine whether changes in 5-HT~2C~R density, transcription, editing, or some alteration in downstream cell signaling account for the tolerance to 5-HT~2C~R stimulation observed in the FC.

5-HT~2C~R distribution has been well characterized by immunohistochemistry in rodent FC, where these receptors are mainly expressed by parvalbumin-positive GABA interneurons ([@CIT0042]). The turnover (5-HIAA/5-HT ratio) assay does not provide information as to whether the decreased inhibitory effect of 5-HT~2C~R activation can be explained by changes at the 5-HT~2C~R themselves or by other changes, notably affecting GABAergic transmission. However, immunohistochemical data indicated no changes in the density of cells expressing 5-HT~2C~R protein in the FC of 5-HTT^-/-^ mice, nor did quantitative RT-PCR show any decrease in 5-HT~2C~R mRNAs (as previously shown with chronic selective serotonin reuptake inhibitors; [@CIT0070]). Our data agree with those of [@CIT0040], who reported no changes in cortical 5-HT~2C~R binding sites in 5-HTT^-/-^ mutants versus 5-HTT^+/+^ mice.

Because 5-HT~2C~R density was not altered, we next explored whether the decrease in 5-HT~2C~R functions might alternatively be explained by alterations in 5-HT~2C~R pre-mRNA editing in 5-HTT^-/-^ mutants. Indeed, [@CIT0018] reported significant editing changes in the cerebral cortex of BALB/c mice after chronic 5-HT reuptake inhibition. However, such changes were not found in C57Bl/6 mice ([@CIT0018]). Also, our assessment of up to 32 mRNAs of the 5-HT~2C~R using capillary electrophoresis ([@CIT0061]) did not reveal any editing change in the FC of 5-HTT^-/-^ mice of this same genetic background ([Figure 3](#F3){ref-type="fig"}).

These negative findings spurred us into setting up an *in vivo* cellular assay to assess the ability of 5-HT~2C~R activation to induce the expression of the IEG *c-fos* mRNA. This assay was validated using 5-HT~2C~R--like immunostaining coupled with *c-fos* mRNA *in situ* hybridization, rather than with a classical pharmacological approach. This choice was made because 5-HT~2C~R antagonists produce on their own distinct patterns of Fos, or *c-fos* mRNA, expression ([@CIT0030]; [@CIT0016]). To avoid strong *c-fos* mRNA induction generated by animal handling during injections, mice were injected remotely using an i.v.-implanted catheter. Contrary to the Fos protein, the expression of *c-fos* mRNA is transient, with maximal expression being reached within 30 minutes after stimulus ([@CIT0066]; [@CIT0030]). In the present study, basal *c-fos* mRNA expression was not likely to reflect animal handling because catheterizations were performed 4 days before the experiment. Furthermore, tubing connection was made 3 hours before i.v. injections.

In these conditions, we found that acute administration of RO-60,0175 increased *c-fos* mRNA expression in 5-HT~2C~R--positive cells in 5-HTT^+/+^ mice, but not in 5-HTT^-/-^ mutants. The latter had, however, an increased baseline expression of *c-fos* mRNA (in agreement with [@CIT0034]), which is very probably related to the increased Fos levels reported after chronic ADs ([@CIT0054]). In 5-HTT^-/-^ mutants, 5-HT~2C~R--mediated responses might be decreased because cells expressing 5-HT~2C~R have blunted intracellular signaling capacities, including those required to trigger *c-fos* mRNA production. Knowing that *c-fos* mRNA induction is linked to a rise in intracellular Ca^2+^ concentration ([@CIT0030]), cells regulated by 5-HT~2C~R might have a diminished capacity to raise intracellular Ca^2+^ levels above baseline in 5-HTT^-/-^ mice.

Major alterations in GABAergic neurons expressing 5-HT~2C~R have been evidenced in 5-HTT^-/-^ mice, including decreased GABA synthesis capacity, reduced GABA~A~ receptor numbers, and lower GABA-stimulated Cl^-^ uptake compared to wild-type mice ([@CIT0021]; [@CIT0027]). In addition, two markers of GABAergic interneurons, the intracellular Ca^2+^ buffering proteins parvalbumin and calbindin, are decreased in 5-HTT^-/-^ mice ([@CIT0027]), as well as in mice chronically treated with fluoxetine ([@CIT0057]), and low parvalbumin concentration is associated with increased Fos expression ([@CIT0036]). Interestingly, [@CIT0082] reported that chronic blockade of 5-HTT desensitizes the excitatory effect of 5-HT on GABAergic interneurons while increasing their basal excitability. In view of these data, we propose a hypothetic mechanism of functional 5-HT~2C~R desensitization, as detailed in [Figure 4](#F4){ref-type="fig"}. Our data suggest that this desensitization does not involve changes at the receptor itself, but implicates downstream signaling pathways. Furthermore, the basal increase in *c-fos* mRNA is interesting, as this IEG has been involved in synaptic plasticity ([@CIT0072]). It is thus possible that consequent neural circuit changes in the FC, impacting the physiology of GABAergic interneurons ([@CIT0057]), also explain the altered behavioral responses of 5-HTT^-/-^ mice.

![Hypothetical mechanisms underlying the decreased 5-HT~2C~ receptor-mediated responses in areas such as the frontal cortex following sustained 5-HT uptake inhibition.\
(A) A deficit in 5-HT reuptake leads to an increased extracellular concentration of 5-HT. Despite this increased synaptic 5-HT, there are no changes in either 5-HT~2C~R mRNA or pre-mRNA editing (B) or 5-HT~2C~R density (C). (D) 5-HT and 5-HT~2C~R agonists exert an excitatory effect on GABAergic cells via Gq protein activation of PLC and IP3-induced mobilization of Ca^2+^ from endoplasmic reticulum. (E) *c-fos* mRNA expression is increased by cell depolarization and elevation in cytosolic \[Ca^2+^\]~c~, normally triggered by 5-HT~2C~R activation (left). (F) Antidepressant drugs and 5-HTT inactivation appear to decrease Ca^2+^ buffering proteins, which would lead to increased basal levels of both \[Ca^2+^\]~c~ and *c-fos* expression ([@CIT0027]; [@CIT0036]; [@CIT0057]; right). (G) The enhanced basal \[Ca^2+^\]~c~ and c-Fos protein would prevent further increases in these intracellular messengers following 5-HT~2C~R activation (right). (H) These alterations in intracellular signaling could somehow be linked to the altered gamma-aminobutyric acid (GABA) ergic transmission observed after 5-HTT inactivation and antidepressant treatments ([@CIT0021]; [@CIT0027]; [@CIT0025]; [@CIT0071]). Overall, long-term 5-HTT inhibition would lead to both an increased basal excitability of these cells and their blunted response to 5-HT~2C~R stimulation ([@CIT0082]).](ijnppy_pyu056_f0004){#F4}

In conclusion, the primary change explaining the decrease in the responsiveness of 5-HT~2C~R in 5-HTT^-/-^ mice might be the high extracellular 5-HT concentration reached after reuptake inactivation, but no secondary changes in 5-HT~2C~R protein, mRNA, or editing were observed in the FC. Although not investigated here, developmentally-triggered changes in 5-HT~2C~R density in the amygdala might explain the mainly anxiogenic profile of 5-HTT^-/-^ mice ([@CIT0040]; [@CIT0055]) as this structure remained responsive to 5-HT~2C~R stimulation in 5-HTT^-/-^ mice ([Figure 2](#F2){ref-type="fig"}). However, the blunted capacity of neurons expressing 5-HT~2C~R in other areas to trigger 5-HT~2C~R--mediated intracellular signaling would strongly limit the expression of anxiety in 5-HTT^-/-^ mice. Such an adaptive functional desensitization of 5-HT~2C~R opens new perspectives not only in the context of AD treatments, but also in relation to 5-HTT polymorphisms predisposing to anxiety disorders.

Statement of Interest
=====================

All authors report no biomedical ﬁnancial interests or potential conﬂicts of interest.

This work was supported by grants from INSERM, UPMC, the European Community (FP7, "Devanx" consortium, F2-2007--201714), and ANR (Sercedit 2008--2010, contract ANR-06-Neuro-045-01). Dr CBP Martin was recipient of a fellowship from the French Ministère de la Recherche during performance of this work. Dr Trigo was supported by Fundacion Alicia Koplowitz. Dr Fink (DA07287, DA034488) and Dr Cunningham (DA024157, DA020087) were supported by the National Institute on Drug Abuse grants. We are especially grateful to Professor KP Lesch (University of Wuerzburg, Germany) for providing 5-HTT mutant mice to set up breeding colonies, to Laurent Vincent and Dr Jean-François Pujol (Biocortech, Paris) for capillary electrophoresis analysis of pre-mRNA editing and Dr Theresa Smith (University of Texas Medical Branch) for her guidance and assistance with CHO cell analyses.
